Abstract
Follow up data of 204 Myeloma patients seen at the Royal Marsden were analysed for factors predicting the overall survival. All these patients were newly diagnosed and went on to receive VAMP/C-VAMP/V-C-VAMP, infusional cytoreductive treatment. 146 of these patients received some form of high dose treatment (Melphalan or Busulfan). A Cox regression analysis was carried out on clinical and laboratory factors just prior to treatment. Multivariate analysis revealed stage (P = 0.0001), Hb (P = 0.03), serum Calcium (P = 0.01) and performance status (P = 0.01) as independent prognostic factors. Beta2 microglobulin was however not included in this analysis as this was not done routinely in the initial patients (n = 51). When however we repeated the analysis after the elimination of these 51 patients, Beta2 microglobulin was the single most important prognostic variable (P
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
